Uwe Wagner

9.5k total citations · 2 hit papers
247 papers, 5.7k citations indexed

About

Uwe Wagner is a scholar working on Oncology, Reproductive Medicine and Immunology. According to data from OpenAlex, Uwe Wagner has authored 247 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 48 papers in Reproductive Medicine and 41 papers in Immunology. Recurrent topics in Uwe Wagner's work include Ovarian cancer diagnosis and treatment (42 papers), Advanced Combustion Engine Technologies (39 papers) and Catalytic Processes in Materials Science (22 papers). Uwe Wagner is often cited by papers focused on Ovarian cancer diagnosis and treatment (42 papers), Advanced Combustion Engine Technologies (39 papers) and Catalytic Processes in Materials Science (22 papers). Uwe Wagner collaborates with scholars based in Germany, United States and Belgium. Uwe Wagner's co-authors include Silke Reinartz, Rolf Müller, Andreas du Bois, Florian Finkernagel, Ignace Vergote, Joseph P. Huston, Julia M. Jansen, Christian Jackisch, Till Adhikary and Jacobus Pfisterer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Uwe Wagner

227 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

2006 540 citations Ignace Vergote, Andreas du Bois et al. Journal of Clinical Oncology profile →
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

2010 410 citations Éric Pujade-Lauraine, Uwe Wagner et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Uwe Wagner Germany	40	1.9k	1.6k	1.3k	1.2k	1.0k	247	5.7k
Rainer Kimmig Germany	52	3.6k 1.9×	3.6k 2.3×	1.2k 0.9×	2.2k 1.9×	1.5k 1.5×	402	10.3k
Christian F. Singer Austria	45	717 0.4×	3.0k 1.9×	455 0.3×	2.0k 1.7×	372 0.4×	267	6.4k
W. Jonat Germany	48	960 0.5×	4.7k 2.9×	494 0.4×	2.0k 1.6×	835 0.8×	298	9.8k
Yonghee Lee South Korea	26	2.2k 1.2×	381 0.2×	335 0.3×	600 0.5×	633 0.6×	97	4.1k
Yan Li China	36	712 0.4×	601 0.4×	357 0.3×	1.4k 1.2×	1.8k 1.7×	354	5.5k
Lynn C. Hartmann United States	59	1.8k 1.0×	4.9k 3.1×	1.1k 0.8×	3.2k 2.7×	1.5k 1.4×	203	13.0k
Faith G. Davis United States	47	384 0.2×	2.5k 1.6×	492 0.4×	2.1k 1.8×	705 0.7×	147	10.4k
Marion Kiechle Germany	43	374 0.2×	2.3k 1.5×	382 0.3×	2.2k 1.9×	560 0.5×	311	6.2k
Akila N. Viswanathan United States	46	1.9k 1.0×	1.4k 0.9×	300 0.2×	859 0.7×	3.0k 2.9×	202	9.2k
Isao Hara Japan	49	301 0.2×	2.3k 1.4×	1.4k 1.1×	2.9k 2.4×	2.1k 2.1×	498	9.2k

Countries citing papers authored by Uwe Wagner

Since Specialization

Citations

This map shows the geographic impact of Uwe Wagner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uwe Wagner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uwe Wagner more than expected).

Fields of papers citing papers by Uwe Wagner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uwe Wagner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uwe Wagner. The network helps show where Uwe Wagner may publish in the future.

Co-authorship network of co-authors of Uwe Wagner

This figure shows the co-authorship network connecting the top 25 collaborators of Uwe Wagner. A scholar is included among the top collaborators of Uwe Wagner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uwe Wagner. Uwe Wagner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Trillsch, Fabian, Bastian Czogalla, Sven� Mahner, et al.. (2025). Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3/LION exploratory analysis. International Journal of Surgery. 111(4). 2914–2922.

Gremke, Niklas, Julia Teply‐Szymanski, A. Stroh, et al.. (2024). NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors—A Retrospective Molecular Tumor Board Analysis. Cancers. 16(8). 1561–1561. 3 indexed citations

Gremke, Niklas, Wolfgang Janni, Markus Wallwiener, et al.. (2024). Proof-of-concept study of a small language model chatbot for breast cancer decision support – a transparent, source-controlled, explainable and data-secure approach. Journal of Cancer Research and Clinical Oncology. 150(10). 451–451. 9 indexed citations

Teply‐Szymanski, Julia, Ramona Erber, Annette Lebeau, et al.. (2023). Klinisch relevante molekularpathologische Diagnostik beim Mammakarzinom. PubMed. 44(1). 39–49. 2 indexed citations

Gremke, Niklas, et al.. (2023). Therapy delay due to COVID-19 pandemic among European women with breast cancer: prevalence and associated factors. Journal of Cancer Research and Clinical Oncology. 149(13). 11749–11757. 4 indexed citations

Gremke, Niklas, et al.. (2023). Initiation of Antiresorptive Drug Treatment during Endocrine Therapy for Breast Cancer—A Retrospective Cohort Study of 161,492 Patients in Germany. Cancers. 15(6). 1847–1847. 2 indexed citations

Gremke, Niklas, et al.. (2023). Resilience of Gynecological and Obstetric Inpatient Care in Central Germany in Times of Repetitive Socioeconomic Shocks—An Epidemiological Study Assessing Standardized Health Services Indicators and Economic Status According to the aG-DRG Catalog. Healthcare. 11(12). 1683–1683. 1 indexed citations

Gremke, Niklas, et al.. (2023). Is there an association between endometriosis and subsequent breast cancer? A retrospective cohort study from Germany. Breast Cancer Research and Treatment. 204(2). 359–365. 2 indexed citations

Wagner, Uwe, et al.. (2022). Use Case Evaluation and Digital Workflow of Breast Cancer Care by Artificial Intelligence and Blockchain Technology Application. Healthcare. 10(10). 2100–2100. 5 indexed citations

10.

Wagner, Uwe, et al.. (2022). Impact of the COVID-19 Pandemic on Delivery of Gynecology and Obstetrics Services at a Maximum Care University Hospital in Germany. Geburtshilfe und Frauenheilkunde. 82(4). 427–440. 5 indexed citations

11.

Schieffer, Bernhard, et al.. (2021). Towards a COVID-19 symptom triad: The importance of symptom constellations in the SARS-CoV-2 pandemic. PLoS ONE. 16(11). e0258649–e0258649. 3 indexed citations

12.

Finkernagel, Florian, Barbara Joos, Andrea Nist, et al.. (2018). Chromatin Binding of c-REL and p65 Is Not Limiting for Macrophage IL12B Transcription During Immediate Suppression by Ovarian Carcinoma Ascites. Frontiers in Immunology. 9. 1425–1425. 11 indexed citations

13.

Baumann, Klaus, Andreas du Bois, Werner Meier, et al.. (2012). A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Annals of Oncology. 23(9). 2265–2271. 67 indexed citations

14.

Pujade-Lauraine, Éric, Uwe Wagner, Val Gebski, et al.. (2010). Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse. Journal of Clinical Oncology. 28(20). 3323–3329. 410 indexed citations breakdown →

15.

Reinartz, Silke, et al.. (2005). Development of a Delivery System for the Continuous Endogenous Release of an Anti-Idiotypic Antibody Against Ovarian Carcinoma. Hybridoma. 24(3). 133–140. 2 indexed citations

16.

Bois, Andreas du, Werner Meier, Hans‐Joachim Lück, et al.. (2002). Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Annals of Oncology. 13(2). 251–257. 41 indexed citations

17.

Schmolling, J., J. Reinsberg, Uwe Wagner, & D. Krebs. (1997). Anti-TAG-72 Antibody B72.3—Immunological and Clinical Effects in Ovarian Carcinoma. Hybridoma. 16(1). 53–58. 10 indexed citations

18.

Wagner, Uwe, et al.. (1997). Immunological Responses to the Tumor-Associated Antigen CA15 in Patients with Advanced Ovarian Cancer Induced by the Murine Monoclonal Anti-idiotype Vaccine ACA125. Hybridoma. 16(1). 33–40. 41 indexed citations

19.

Schlebusch, H., et al.. (1995). A Monoclonal Antiidiotypic Antibody ACA 125 Mimicking the Tumor-Associated Antigen CA 125 for Immunotherapy of Ovarian Cancer. Hybridoma. 14(2). 167–174. 28 indexed citations

20.

Wagner, Uwe, et al.. (1990). Detection of phosphate ester pesticides and the triazine herbicide atrazine in human milk, cervical mucus, follicular and sperm fluid.. Fresenius Journal of Analytical Chemistry. 337(1). 77–78. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact